7 news items
MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA's Approval of a Telomerase Inhibitor Agent Therapy
MAIA
7 Jun 24
and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates
MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent
MAIA
6 Jun 24
preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully
MAIA Biotechnology Reveals New Clinical Data Showing THIO's Strong Efficacy in Non-Small Cell Lung Cancer
MAIA
4 Jun 24
research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing
MAIA Biotechnology (NYSE: MAIA) Makes Strategic Moves: Key Presentations, New Funding, and Leadership Changes Drive Innovation
ABBV
JNJ
LLY
21 May 24
, THIO. This platform provides MAIA with a significant opportunity to showcase its cutting-edge research and development efforts to potential partners
MAIA Biotechnology to Present at the BIO International Convention 2024
MAIA
17 May 24
and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii
1zw7b29valbz5by743oc9ln2sc39 i1o
MAIA
16 May 24
) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our
h71mwq4jt51svtd1981r2c65zu 5n
MAIA
5 Apr 24
, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates
- Prev
- 1
- Next